William Cook
Cardiovascular Disease · Wauchula, FLNPI 1699700930
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $425 and has fallen 92.7% since, to $31 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in FL, where the typical reported total is $2,774.
Across 91 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$268
- Abbott$229
- AstraZeneca$148
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$95
- Amgen$90
- Novartis$88
- plus $623 from 16 others
What the payments were for
- Food & beverage$1,52299%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $268 |
| Abbott | 11 | $229 |
| AstraZeneca(2 entities) | 10 | $148 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $95 |
| Amgen | 4 | $90 |
| Novartis | 6 | $88 |
| Boston Scientific | 5 | $87 |
| Biotronik Inc. | 5 | $84 |
| Merck | 5 | $79 |
| Cvrx, Inc. | 4 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Pfizer | 3 | $41 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Philips North America LLC | 1 | $35 |
| Kestra Medical Technology Services, Inc. | 1 | $33 |
| Boehringer Ingelheim | 2 | $32 |
| Atricure, Inc. | 1 | $31 |
| Medtronic | 2 | $25 |
| Astellas Pharma US Inc | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $5 |
How this compares
$1,540 in reported general payments places this provider in the 35th percentile of 1,740 cardiovascular disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $22,426 |
| Amlodipine Besylate | 53 | $340 |
| ClopidogrelClopidogrel Bisulfate | 34 | $317 |
| Losartan Potassium | 18 | $193 |
| Atorvastatin Calcium | 23 | $154 |
| Lisinopril | 20 | $124 |
| Carvedilol | 11 | $105 |
| Metoprolol Tartrate | 14 | $84 |
| Furosemide | 14 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $41 | $22,42620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Wauchula
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.